GLP-1 is already in your workforce - here's the duty of care

The largest metabolic shift in a generation is not arriving in your workforce. It is already there. GLP-1 medications have moved from specialist clinics to everyday conversation in a few short years, and a growing share of employees are taking them privately: prescribed elsewhere, paid for personally, invisible to any corporate programme.

That invisibility is the problem. Not because the medication is wrong for the people taking it, but because rapid metabolic change without objective measurement and clinical oversight carries real risks: muscle loss, nutritional gaps, rebound, and a workforce quietly running one of the biggest health experiments in history with no baseline on file.

Why this lands on the employer's desk

Employers did not choose this shift, but they inherit its consequences: energy, body composition and mental state all move with metabolic change, and all of them show up at work. In the metabolic and pre-diabetic range, where a large share of the modern knowledge workforce sits, the questions get sharper. Who is monitoring the change? Against what baseline? With what clinical accountability?

Duty of care used to mean an annual camp and an assistance line. In the GLP-1 era it means something more specific: knowing, objectively and privately, what state your people's metabolic health is in, and giving every individual a physician-overseen picture of their own biology before and during any major change.

The responsible position is not "for" or "against" GLP-1. It is measured: an objective baseline, physician oversight, and a trajectory that shows what is actually happening.

The measured position

What a responsible programme looks like

• An objective metabolic baseline for every enrolled employee, from 200+ biomarkers across 7 panels
• A named physician signing every report: physician-reviewed, never "AI-diagnosed"
• Quarterly re-measurement, so change is tracked rather than assumed
• Aggregate-only visibility for the employer: the metabolic picture of the workforce, never the individual

Turning an emerging risk into demonstrable care

Handled this way, the GLP-1 era stops being a liability question and becomes the clearest possible demonstration of care. The employee gets a private, clinical view of their own biology and a plan built on the 11+1 lifestyle pillars that protects muscle, nutrition and sleep through any metabolic change. The employer gets what it has never had: an aggregate, anonymised view of metabolic risk, and proof that it is moving in the right direction, quarter after quarter.

The window matters. Baselines are most valuable when they are taken early. Every quarter that passes without measurement is a quarter of change you can never reconstruct. A 50-100-person pilot puts the baseline in place in weeks, and turns the biggest metabolic shift in a generation into a measured, defensible programme of care.